Statements (22)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:clinical_trial
|
| gptkbp:clinicalTrials.govIdentifier |
NCT03882970
|
| gptkbp:comparatorDrug |
gptkb:insulin_degludec
|
| gptkbp:conditionStudied |
gptkb:type_2_diabetes
|
| gptkbp:endPoint |
change in HbA1c
change in body weight |
| gptkbp:enrollment |
1444
|
| gptkbp:fullName |
A Study of Tirzepatide (LY3298176) Versus Insulin Degludec in Participants With Type 2 Diabetes
|
| https://www.w3.org/2000/01/rdf-schema#label |
SURPASS-3
|
| gptkbp:location |
multinational
|
| gptkbp:period |
Phase 3
|
| gptkbp:primaryCompletionDate |
2021
|
| gptkbp:publishedIn |
https://www.nejm.org/doi/full/10.1056/NEJMoa2107519
|
| gptkbp:result |
tirzepatide superior to insulin degludec for HbA1c and weight reduction
|
| gptkbp:sponsor |
gptkb:Eli_Lilly_and_Company
|
| gptkbp:startDate |
2019
|
| gptkbp:studiedDrug |
gptkb:tirzepatide
|
| gptkbp:studyType |
randomized
open-label parallel assignment |
| gptkbp:bfsParent |
gptkb:tirzepatide
|
| gptkbp:bfsLayer |
7
|